Rucaparib: A Consistent Treatment Option for BRCA-Mutated mCRPC Across Age Groups
Автор: Endless Stories
Загружено: 2025-12-06
Просмотров: 0
Rucaparib, a promising treatment for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), has shown consistent benefits across all age groups. The updated data from the TRITON3 trial reinforces its effectiveness, with a significant improvement in radiographic progression-free survival (rPFS) compared to physician's choice of therapy. This video explores the key findings, including the strengthened benefit with age, and the manageable safety profile of rucaparib. Learn how this treatment option can make a difference for patients with mCRPC, regardless of age.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке: